Article Text

Download PDFPDF

516 CD47 x B7-H3 bispecific antibody offers a new strategy for treating B7-H3+/CD47+ tumors
  1. Xinhua Wang,
  2. Oi Kwan Wong,
  3. Lei Shi,
  4. Qi Fei,
  5. Leonard Post and
  6. Xiaocheng Chen
  1. Virtuoso Therapeutics, San Mateo, CA, USA


Background B7-H3, also known as CD276, is a member of the B7 family and highly expressed in multiple types of human cancers. B7-H3 overexpression has been frequently associated with poor prognosis. In addition, B7-H3 plays an immunoregulatory role in the T cell and NK activation, and thus has been highlighted as an attractive target for cancer therapy. CD47/SIRPa axis is an important checkpoint of innate immune system, CD47 interacts with its ligand signal regulatory protein-alpha (SIRPa) on myeloid cells, conveys a ‘don’t eat me’ signal and blocks macrophage mediated phagocytosis.1 Tumor cells, which express high level of CD47, exploit this mechanism to evade from immune surveillance. CD47 is considered a prominent target for cancer treatment. However, the wide expression of CD47 on normal cells could cause safety issues, such as anemia and thrombocytopenia. To address these challenges, we developed a novel CD47xB7-H3 bispecific antibody, which selectively targets tumors expressing both CD47 and B7-H3.2

Methods Anti-B7-H3 antibodies were generated from mouse hybridoma and rabbit B cell cloning. A panel of bispecific CD47xB7-H3 antibodies were generated and characterized by a series of in vitro assays including FACS binding, SIRPa blocking, antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), red blood cells (RBC) binding and hemagglutination. In vivo efficacy of CD47xB7-H3 bispecific antibody was evaluated in xenograft tumor models that co-express B7-H3 and CD47.

Results Novel anti-B7-H3 antibodies were characterized for their binding affinity and epitope specificity. Anti-B7-H3 antibodies were paired with our proprietary anti-CD47 antibody to generate CD47xB7-H3 bispecific antibodies. VBI-009, the lead CD47xB7-H3 bispecific antibody, was identified by its best overall activities across various in vitro and in vivo functional assays. It exhibits potent SIRPa blocking, ADCP and ADCC activities on CD47+/B7-H3+ tumor cells. However, it has little or no activity on cells that do not express B7-H3. VBI-009 has no significant binding to red blood cells and doesn’t cause hemagglutination. In vivo studies have shown that VBI-009 is effective against lung cancer models with complete tumor growth inhibition.

Conclusions Our findings suggest that the novel CD47xB7-H3 bispecific antibody selectively binds to CD47+/B7-H3+ tumor cells and has minimum RBC binding compared to the bivalent CD47 monoclonal antibodies. The bispecific antibody shows potent CD47/SIRPa blocking activity on B7-H3 overexpressing tumor cells. It also demonstrates strong functional activities in vitro and efficacy in vivo on B7-H3 and CD47 positive tumor cells. CD47xB7-H3 bispecific antibody offers a novel approach for treating CD47+/B7-H3+ tumors.


  1. Chao M, Weissman I, Majeti R. The CD47-SIRPa Pathway in Cancer Immune Evasion and Potential Therapeutic Implications. Curr Opin Immunol. 2012; 24(2): 225–232.

  2. Zhou W, Jin W. B7-H3/CD276. An Emerging Cancer Immunotherapy. Front Immunol. 2021; 12: 701006

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.